Home/Pipeline/SPC-14

SPC-14

Alzheimer’s Disease

PreclinicalResearch

Key Facts

Indication

Alzheimer’s Disease

Phase

Preclinical

Status

Research

Company

Silo Pharma

About Silo Pharma

Silo Pharma is a Nasdaq-listed biotech focused on developing novel therapeutics for central nervous system disorders and chronic pain through a capital-efficient licensing and development model. Its core strategy involves in-licensing promising candidates from academic partners and advancing them via the FDA's 505(b)(2) regulatory pathway to reduce time and cost. Key assets include SPC-15, a prophylactic intranasal treatment for stress-induced disorders, and SP-26, a ketamine-based implant for fibromyalgia. The company aims to address significant unmet medical needs in large, growing markets with limited treatment options.

View full company profile

Therapeutic Areas

Central Nervous System Psychiatry Chronic Pain

Other Alzheimer’s Disease Drugs

Drug	Company	Phase	Status
RASTRUM™ 3D Alzheimer’s Disease Model	Inventia Life Science	Pre‑clinical	Active
Masitinib	AB Science	Phase 3	Active
Vaxine Alzheimer’s Disease Vaccine	Vaxine	Preclinical	Active
Leronlimab	CytoDyn	Phase 1	Phase in progress
Sovateltide	Pharmazz	Preclinical	Active
Alzheimer's Drug	Dawah Pharmaceuticals	Development	Active
Alzheimer’s Clinical Trials	Boston Clinical Trials	Not Specified (Typically Phase 2-3)	Active
ONO-2020	Deciphera Pharmaceuticals	Phase 2	Active
Blarcamesine (ANAVEX®2-73)	Anavex Life Sciences	Phase 2b/3	Ongoing